Clinical reassessment of malignant hyperthermia in Abitibi-Temiscamingue

Canadian Journal of Anaesthesia

Volumn 44, Issue 7, 1997, Pages 696-701

  Bachand, Mychelle ^a   Vachon, Nathalie ^a   Boisvert, Mireille ^c   Mayer, Francine M ^c   Chartrand, Daniel ^b  

^a Centre Hospitalier Rouyn Noranda   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; CHILD; FAMILY; FEMALE; GENEALOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT HYPERTHERMIA; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0030726334     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03013380     Document Type: Article

References (15)

1. Britt BA. Malignant hyperthermia-a review. In: Schönbaum E, Lomax P (Eds.). Thermoregulation: Pathology, Pharmacology and Therapy. New York: Pergamon Press Inc., 1991: 179-92.
2. Gronert GA, Antognini JF. Malignant hyperthermia. In: RD Miller (Ed.). Anesthesia, 2nd ed. New York: Churchill Livingstone, 1986: 1075-93.
3. MacLennan DH, Duff C, Zorzato F, et al. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature 1990; 343: 559-61.
4. Levitt RC, Olckers A, Meyers S, et al. Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics 1992; 14: 562-6.
5. 2/δ-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Hum Mol Genet 1994; 3 : 969-75.
6. Sudbrak R, Procaccio V, Klausnitzer M, et al. Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. Am J Hum Genet 1995; 56: 684-91.
7. Levitt RC. Prospects for the diagnosis of malignant hyperthermia susceptibility using molecular genetic approaches. Anesthesiology 1992; 76: 1039-48.
8. MacLennan DH. Discordance between phenotype and genotype in malignant hyperthermia. Curr Opin Neurol 1995; 8: 397-401.
9. Larach MG, for the North American Malignant Hyperthermia Group. Standardization of the caffeine halothane muscle contracture test. Anesth Analg 1989; 69: 511-5.
10. Larach MG, Localio AR, Allen GC, et al. A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology 1994; 80: 771-9.
11. Sato N, Brum JM, Mitsumoto H, DeBoer GE. Effects of cocaine on the contracture response to 1% halothane in patients undergoing diagnostic muscle biopsy for malignant hyperthermia. Can J Anaesth 1995; 42: 158-62.
12. Islander G, Henriksson K-G, Ranklev-Twetman E. Malignant hyperthermia susceptibility without central core disease (CCD) in a family where CCD is diagnosed. Neuromuscul Disord 1995; 5 :125-7.
13. Fletcher JE, Rosenberg H, Pathophysiology of malignant hyperthermia. In: Hopkins PM, Ellis FR (Eds.). Hyperthermic and Hypermetabolic Disorders. Cambridge: Cambridge University Press. 1996: 132-56.
14. West SP. Genetics of malignant hyperthermia. In: Hopkins PM, Ellis FR (Eds.). Hyperthermic and Hypermetabolic Disorders. Cambridge: Cambridge University Press. 1996: 184-201.
15. Larach MG, Landis JR, Shirk SJ, Diaz M, for The North American Malignant Hyperthermia. Registry. Prediction of malignant hyperthermia susceptibility in man: improving sensitivity of the caffeine halothane contracture test. Anesthesiology 1992; 77: A1052.